In contrast, 3xTg-AD mice subjected to the anti-TNFSF10 mAb treatment exhibited a significant reduction in plaque burden, evidenced by decreased total Aβ immunostaining and smaller plaque size (μm2) in both the brain and the spleen (Fig. 8 panel a-d). The gene discussed is TNFSF10; the disease is Alzheimer disease.